Dr. Brian Dixon explains new findings from a CDC study about the effectiveness of mRNA COVID-19 boosters for immunocompromised adults.
Transcript:
Previously, we looked at the primary series and a single booster dose. Here we’re looking at individuals who have more than one booster. This population had access to additional boosters early. So I think what’s new here is that we’re looking at the effectiveness of additional boosters, and there is added protection with the additional booster. I think the other thing that’s new here is that we’re looking at this during the most recent time period (August 2022).
With the new BA.4, BA.5 strain, individuals with immunocompromised conditions who have received four doses of the vaccine, they have moderate protection against COVID-19, but the protection they have is lower than the general population. One, they need to take extra precautions to prevent from getting sick in the first place, and second, when they are sick, they definitely need to be the ones seeking out these treatments that are in the marketplace to help further prevent severe consequences of COVID-19.
